Clinical Report: Dana-Farber Researchers Receive AACR 2026 Awards

Overview

Dr. Eliezer Van Allen and Dr. Kimberly Stegmaier from Dana-Farber Cancer Institute have been awarded the AACR 2026 Scientific Achievement Awards for their contributions to cancer research. Van Allen is recognized for his work in precision oncology, while Stegmaier is honored for her advancements in pediatric cancer research.

Background

The AACR Scientific Achievement Awards recognize outstanding contributions to cancer research, highlighting the importance of translational and clinical research in improving cancer treatment. Dr. Van Allen's work focuses on integrating cancer genomics with computational biology, while Dr. Stegmaier's research addresses the unique challenges of pediatric cancers.

Data Highlights

No numerical data or trial data is provided in the source material.

Key Findings

• Dr. Eliezer Van Allen received the AACR-Waun Ki Hong Award for his contributions to precision oncology.
• Van Allen's research has defined genomic mechanisms underlying resistance to targeted therapies.
• Dr. Kimberly Stegmaier received the AACR-St. Baldrick’s Foundation Award for her work in pediatric cancer research.
• Stegmaier's research has led to foundational genomic discoveries in childhood cancers.
• Both researchers will present award lectures during the AACR Annual Meeting 2026.

Clinical Implications

The recognition of these researchers highlights the role of genomic research in developing targeted therapies for cancer.

Conclusion

The AACR 2026 Scientific Achievement Awards celebrate advancements in cancer research.

Related Resources & Content

1. Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
2. Dana-Farber Research News 04.15.2026
3. AACR Announces 2018 Special Recognition Awards
4. Three Dana-Farber Cancer Institute scientific leaders elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026
5. New First-Line Targeted Therapy Recommendations Among Updated ASCO Guidance on Gastroesophageal Cancer Management
6. New First-Line Targeted Therapy Recommendations Among Updated ASCO Guidance on Gastroesophageal Cancer Management - The ASCO Post
7. Drug Trials Snapshots: REVUFORJ | FDA
8. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults - PubMed